Jaguar Health (JAGX) EPS (Weighted Average and Diluted) (2016 - 2026)
Jaguar Health (JAGX) reported EPS (Weighted Average and Diluted) of -$13.6 for Q1 2026, up 97.67% year-over-year from -$6.88 in Q1 2025, and down 3677.78% quarter-over-quarter from -$0.36 in Q4 2025.
Jaguar Health (JAGX) EPS (Weighted Average and Diluted) (2016 - 2026) Analysis & Trends
Jaguar Health (JAGX) has 10 years of EPS (Weighted Average and Diluted) data on file, last reported at -$13.6 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$13.6, up 97.67% year-over-year; the trailing twelve-month figure through Mar 2026 was -$30.5 (up 94.86% YoY), and the FY2025 annual result was -$22.97, up 82.42% from the prior year.
- EPS (Weighted Average and Diluted) declined to -$13.6 in Q1 2026 per JAGX's latest filing, from -$0.36 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $20.03 in Q4 2024 and troughed at -$2545.7 in Q4 2023.
- A 5-year average of -$197.83 and a median of -$10.26 in 2025 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2023 and 2024: EPS (Weighted Average and Diluted) slumped 578663.64% in 2023, then surged 100.79% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.44 in 2022, then plunged by 578663.64% to -$2545.7 in 2023, then surged by 100.79% to $20.03 in 2024, then plunged by 101.8% to -$0.36 in 2025, then plunged by 3677.78% to -$13.6 in 2026.
- Business Quant data shows JAGX's EPS (Weighted Average and Diluted) at -$13.6 in Q1 2026, -$0.36 in Q4 2025, and -$6.28 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 0.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -0.61 |
| 10 | Jaguar Health | 1.44 Mn | -10.19 Mn | 19.11 Mn | -13.60 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.60 |
| Dec 31, 2025 | -0.36 |
| Sep 30, 2025 | -6.28 |
| Jun 30, 2025 | -10.26 |
| Mar 31, 2025 | -584.45 |
| Dec 31, 2024 | 20.03 |
| Sep 30, 2024 | -26.29 |
| Jun 30, 2024 | -2.66 |
| Mar 31, 2024 | -87.12 |
| Dec 31, 2023 | -2,545.68 |
| Sep 30, 2023 | -22.50 |
| Jun 30, 2023 | -41.35 |
| Mar 31, 2023 | -2.39 |
| Dec 31, 2022 | 0.44 |
| Sep 30, 2022 | -8.83 |
| Jun 30, 2022 | -8.77 |
| Mar 31, 2022 | -23.10 |
| Dec 31, 2021 | -87.35 |
| Sep 30, 2021 | -0.27 |
| Jun 30, 2021 | -0.31 |